BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 18524582)

  • 1. Discovery of new binding elements in DPP-4 inhibition and their applications in novel DPP-4 inhibitor design.
    Liang GB; Qian X; Biftu T; Singh S; Gao YD; Scapin G; Patel S; Leiting B; Patel R; Wu J; Zhang X; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2008 Jul; 18(13):3706-10. PubMed ID: 18524582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery, SAR, and X-ray structure of novel biaryl-based dipeptidyl peptidase IV inhibitors.
    Qiao L; Baumann CA; Crysler CS; Ninan NS; Abad MC; Spurlino JC; Desjarlais RL; Kervinen J; Neeper MP; Bayoumy SS; Williams R; Deckman IC; Dasgupta M; Reed RL; Huebert ND; Tomczuk BE; Moriarty KJ
    Bioorg Med Chem Lett; 2006 Jan; 16(1):123-8. PubMed ID: 16236500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of DPP IV inhibitors by pharmacophore modeling and QSAR analysis followed by in silico screening.
    Al-Masri IM; Mohammad MK; Taha MO
    ChemMedChem; 2008 Nov; 3(11):1763-79. PubMed ID: 18989859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, biological evaluation and structural determination of beta-aminoacyl-containing cyclic hydrazine derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors.
    Ahn JH; Shin MS; Jun MA; Jung SH; Kang SK; Kim KR; Rhee SD; Kang NS; Kim SY; Sohn SK; Kim SG; Jin MS; Lee JO; Cheon HG; Kim SS
    Bioorg Med Chem Lett; 2007 May; 17(9):2622-8. PubMed ID: 17331715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin.
    Biftu T; Scapin G; Singh S; Feng D; Becker JW; Eiermann G; He H; Lyons K; Patel S; Petrov A; Sinha-Roy R; Zhang B; Wu J; Zhang X; Doss GA; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3384-7. PubMed ID: 17433672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of beta-homophenylalanine based pyrrolidin-2-ylmethyl amides and sulfonamides as highly potent and selective inhibitors of dipeptidyl peptidase IV.
    Nordhoff S; Cerezo-Gálvez S; Deppe H; Hill O; López-Canet M; Rummey C; Thiemann M; Matassa VG; Edwards PJ; Feurer A
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4201-3. PubMed ID: 19515557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [(S)-gamma-(4-Aryl-1-piperazinyl)-l-prolyl]thiazolidines as a novel series of highly potent and long-lasting DPP-IV inhibitors.
    Yoshida T; Sakashita H; Akahoshi F; Hayashi Y
    Bioorg Med Chem Lett; 2007 May; 17(9):2618-21. PubMed ID: 17317162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of 1,4-diazepan-2-one containing dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes.
    Liang GB; Qian X; Feng D; Biftu T; Eiermann G; He H; Leiting B; Lyons K; Petrov A; Sinha-Roy R; Zhang B; Wu J; Zhang X; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2007 Apr; 17(7):1903-7. PubMed ID: 17291750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The reversed binding of beta-phenethylamine inhibitors of DPP-IV: X-ray structures and properties of novel fragment and elaborated inhibitors.
    Nordhoff S; Cerezo-Gálvez S; Feurer A; Hill O; Matassa VG; Metz G; Rummey C; Thiemann M; Edwards PJ
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1744-8. PubMed ID: 16376544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of non-covalent dipeptidyl peptidase IV inhibitors which induce a conformational change in the active site.
    Sheehan SM; Mest HJ; Watson BM; Klimkowski VJ; Timm DE; Cauvin A; Parsons SH; Shi Q; Canada EJ; Wiley MR; Ruehter G; Evers B; Petersen S; Blaszczak LC; Pulley SR; Margolis BJ; Wishart GN; Renson B; Hankotius D; Mohr M; Zechel JC; Michael Kalbfleisch J; Dingess-Hammond EA; Boelke A; Weichert AG
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1765-8. PubMed ID: 17239592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational design of novel glycomimetics: inhibitors of concanavalin A.
    Welch KT; Turner TA; Preast CE
    Bioorg Med Chem Lett; 2008 Dec; 18(24):6573-5. PubMed ID: 18990567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Affinity-based ranking of ligands for DPP-4 from mixtures.
    Adam GC; Meng J; Athanasopoulos J; Zhang X; Chapman KT
    Bioorg Med Chem Lett; 2007 May; 17(9):2404-7. PubMed ID: 17337342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico fragment-based discovery of DPP-IV S1 pocket binders.
    Rummey C; Nordhoff S; Thiemann M; Metz G
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1405-9. PubMed ID: 16321524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-aminophenylalanine and 4-aminocyclohexylalanine derivatives as potent, selective, and orally bioavailable inhibitors of dipeptidyl peptidase IV.
    Duffy JL; Kirk BA; Wang L; Eiermann GJ; He H; Leiting B; Lyons KA; Patel RA; Patel SB; Petrov A; Scapin G; Wu JK; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2007 May; 17(10):2879-85. PubMed ID: 17350841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (3R)-3-amino-4-(2,4,5-trifluorophenyl)-N-{4-[6-(2-methoxyethoxy)benzothiazol-2-yl]tetrahydropyran-4-yl}butanamide as a potent dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Nitta A; Fujii H; Sakami S; Nishimura Y; Ohyama T; Satoh M; Nakaki J; Satoh S; Inada C; Kozono H; Kumagai H; Shimamura M; Fukazawa T; Kawai H
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5435-8. PubMed ID: 18819797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors.
    Anderson M; Andrews DM; Barker AJ; Brassington CA; Breed J; Byth KF; Culshaw JD; Finlay MR; Fisher E; McMiken HH; Green CP; Heaton DW; Nash IA; Newcombe NJ; Oakes SE; Pauptit RA; Roberts A; Stanway JJ; Thomas AP; Tucker JA; Walker M; Weir HM
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5487-92. PubMed ID: 18815031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The structural comparison of the bacterial PepX and human DPP-IV reveals sites for the design of inhibitors of PepX activity.
    Rigolet P; Xi XG; Rety S; Chich JF
    FEBS J; 2005 Apr; 272(8):2050-9. PubMed ID: 15819895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog.
    Rasmussen HB; Branner S; Wiberg FC; Wagtmann N
    Nat Struct Biol; 2003 Jan; 10(1):19-25. PubMed ID: 12483204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of potent amido- and benzyl-substituted cis-3-amino-4-(2-cyanopyrrolidide)pyrrolidinyl DPP-IV inhibitors.
    Corbett JW; Dirico K; Song W; Boscoe BP; Doran SD; Boyer D; Qiu X; Ammirati M; Vanvolkenburg MA; McPherson RK; Parker JC; Cox ED
    Bioorg Med Chem Lett; 2007 Dec; 17(24):6707-13. PubMed ID: 17977724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of aminoethyl pyrrolo dihydroisoquinolinones as novel poly(ADP-ribose) polymerase-1 inhibitors.
    Branca D; Cerretani M; Jones P; Koch U; Orvieto F; Palumbi MC; Rowley M; Toniatti C; Muraglia E
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4042-5. PubMed ID: 19553107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.